Overview

This study focuses on improving heart function in patients with life-threatening blood infections (septic shock). When the body fights severe infections, the heart sometimes struggles to pump blood effectively, which can lead to dangerous complications. Current treatments like intravenous fluids and blood pressure medications have limitations in protecting heart function.

This multicenter clinical trial aims to evaluate whether adding Shenfu Injection - a traditional Chinese medicine preparation widely used to enhance cardiac function in cardiovascular diseases - to standard therapies can:

1. Prevent myocardial dysfunction during septic shock
2. Accelerate cardiac recovery if complications occur
3. Improve overall survival and clinical outcomes The randomized controlled design will compare therapeutic effects between two groups: one receiving standard septic shock treatment alone, and the other receiving standard treatment combined with Shenfu Injection.

Eligibility

Inclusion Criteria:

-

1. Patients clinically diagnosed with septic shock must meet the diagnostic criteria of Sepsis 3.0;

-

2. Age ≥ 18 years.

Exclusion Criteria:

-

1. Pregnant or breastfeeding women;

-

       2. Individuals with a history of allergies or known hypersensitivity to Ginseng
          and Aconite Injection or its components;

-

       3. Severe underlying diseases that may affect prognosis, including uncontrolled
          malignant tumors with multiple metastases that are unresectable, hematological
          disorders, cachexia, persistent active bleeding, severe malnutrition, HIV,
          etc.;

-

       4. Severe cardiac conditions within the last three months, including acute
          unstable myocardial infarction, dilated cardiomyopathy, acute coronary
          syndrome, acute or chronic valvular heart disease, and congestive heart failure
          (New York Heart Association [NYHA] Class IV);

-

       5. Any of the following medical procedures performed within the last three months:
          any form of cardiac surgery, thoracotomy, external cardiac compression,
          defibrillation, direct current cardioversion, or trauma;

-

6. Use of Ginseng and Aconite Injection for less than 48 hours;

-

7. Patients expected to die within 48 hours;

-

8. Patients deemed unsuitable for this study by the investigator.